ChromaDex logo
Cellular Health Market Leader Tru Niagen® Launches Online in Australia
March 23, 2020 06:30 ET | ChromaDex Corporation
ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia LOS ANGELES, March 23, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce...
ChromaDex logo
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
March 12, 2020 16:44 ET | ChromaDex Corporation
LOS ANGELES, March 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client,...
ChromaDex logo
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
March 10, 2020 16:01 ET | ChromaDex Corporation
Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.Tru...
ChromaDex logo
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
February 27, 2020 06:30 ET | ChromaDex Corporation
LOS ANGELES, Feb. 27, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science,...
ChromaDex logo
ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020
February 25, 2020 06:30 ET | ChromaDex Corporation
LOS ANGELES, Feb. 25, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results...
ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science
February 12, 2020 06:30 ET | ChromaDex Corporation
LOS ANGELES, Feb. 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® (nicotinamide riboside) as a supplement...
ChromaDex logo
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide
February 03, 2020 06:30 ET | ChromaDex Corporation
LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the expansion of its industry-leading reference standards business with a new line of cannabinoid (CBD)...
ChromaDex logo
ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
January 15, 2020 06:30 ET | ChromaDex Corporation
LOS ANGELES, Jan. 15, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to...
ChromaDex logo
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
January 06, 2020 06:30 ET | ChromaDex Corporation
LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science,...
ChromaDex logo
ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®
December 16, 2019 06:30 ET | ChromaDex Corporation
LOS ANGELES, Dec. 16, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded...